Acquired Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acquired hemophilia A markets reached a value of US$ 9.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.34% during 2024-2034.
The acquired hemophilia A market has been comprehensively analyzed in IMARC's new report titled "Acquired Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder characterized by the development of antibodies, called inhibitors, that target and neutralize clotting factor VIII, a vital protein responsible for normal blood coagulation. This disease typically occurs later in life, often affecting individuals with no prior history of bleeding disorders. The symptoms of the illness are marked by spontaneous and excessive bleeding that can manifest as prolonged or uncontrollable bleeding from minor injuries, mucous membranes, and soft tissues. Bruising, joint pain, and gastrointestinal or urinary tract bleeding may also occur. These indications can be severe and require immediate medical attention. Diagnosing acquired hemophilia A involves a comprehensive assessment of bleeding symptoms, medical history, and laboratory tests to detect the presence of clotting factor inhibitors. Coagulation studies, such as the activated partial thromboplastin time and clotting factor assays, are also utilized to confirm the diagnosis by revealing prolonged clotting times and reduced factor VIII activity.
The increasing prevalence of bleeding disorders that can cause the sudden development of autoantibodies against clotting factor VIII is primarily driving the acquired hemophilia A market. In addition to this, the inflating utilization of efficacious treatments, such as bypassing agents and immune tolerance induction, is creating a positive outlook for the market. These interventions, tailored to neutralize inhibitors and enhance coagulation, play a pivotal role in managing and mitigating the severity of bleeding episodes. Moreover, the widespread integration of personalized treatment approaches customized to individual patient profiles, leveraging advancements in diagnostics and precision medicine, is further bolstering the market growth. Apart from this, the rising usage of physical and rehabilitative strategies on account of their various benefits, like enhancing joint mobility, muscular strength, and overall quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of rituximab, an anti-CD20 monoclonal antibody, since it helps to mitigate the immune response that leads to inhibitor formation, is also augmenting the market growth. Furthermore, the escalating demand for innovative techniques, such as gene editing and targeted therapies, that can rectify the underlying genetic aberrations responsible for the disorder is expected to drive the acquired hemophilia A market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acquired hemophilia A market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acquired hemophilia A and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acquired hemophilia A market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acquired hemophilia A market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acquired hemophilia A market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acquired hemophilia A marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acquired hemophilia A market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acquired hemophilia A market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acquired hemophilia A market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acquired hemophilia A across the seven major markets?
What is the number of prevalent cases (2018-2034) of acquired hemophilia A by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acquired hemophilia A by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acquired hemophilia A across the seven major markets?
What is the size of the acquired hemophilia A patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acquired hemophilia A?
What will be the growth rate of patients across the seven major markets?
Acquired Hemophilia A: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acquired hemophilia A drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acquired hemophilia A market?
What are the key regulatory events related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by status related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by phase related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by route of administration related to the acquired hemophilia A market?
The acquired hemophilia A market has been comprehensively analyzed in IMARC's new report titled "Acquired Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder characterized by the development of antibodies, called inhibitors, that target and neutralize clotting factor VIII, a vital protein responsible for normal blood coagulation. This disease typically occurs later in life, often affecting individuals with no prior history of bleeding disorders. The symptoms of the illness are marked by spontaneous and excessive bleeding that can manifest as prolonged or uncontrollable bleeding from minor injuries, mucous membranes, and soft tissues. Bruising, joint pain, and gastrointestinal or urinary tract bleeding may also occur. These indications can be severe and require immediate medical attention. Diagnosing acquired hemophilia A involves a comprehensive assessment of bleeding symptoms, medical history, and laboratory tests to detect the presence of clotting factor inhibitors. Coagulation studies, such as the activated partial thromboplastin time and clotting factor assays, are also utilized to confirm the diagnosis by revealing prolonged clotting times and reduced factor VIII activity.
The increasing prevalence of bleeding disorders that can cause the sudden development of autoantibodies against clotting factor VIII is primarily driving the acquired hemophilia A market. In addition to this, the inflating utilization of efficacious treatments, such as bypassing agents and immune tolerance induction, is creating a positive outlook for the market. These interventions, tailored to neutralize inhibitors and enhance coagulation, play a pivotal role in managing and mitigating the severity of bleeding episodes. Moreover, the widespread integration of personalized treatment approaches customized to individual patient profiles, leveraging advancements in diagnostics and precision medicine, is further bolstering the market growth. Apart from this, the rising usage of physical and rehabilitative strategies on account of their various benefits, like enhancing joint mobility, muscular strength, and overall quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of rituximab, an anti-CD20 monoclonal antibody, since it helps to mitigate the immune response that leads to inhibitor formation, is also augmenting the market growth. Furthermore, the escalating demand for innovative techniques, such as gene editing and targeted therapies, that can rectify the underlying genetic aberrations responsible for the disorder is expected to drive the acquired hemophilia A market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acquired hemophilia A market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acquired hemophilia A and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acquired hemophilia A market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acquired hemophilia A market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acquired hemophilia A market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acquired hemophilia A marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acquired hemophilia A market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acquired hemophilia A market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acquired hemophilia A market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acquired hemophilia A across the seven major markets?
What is the number of prevalent cases (2018-2034) of acquired hemophilia A by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acquired hemophilia A by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acquired hemophilia A across the seven major markets?
What is the size of the acquired hemophilia A patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acquired hemophilia A?
What will be the growth rate of patients across the seven major markets?
Acquired Hemophilia A: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acquired hemophilia A drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acquired hemophilia A market?
What are the key regulatory events related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by status related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by phase related to the acquired hemophilia A market?
What is the structure of clinical trial landscape by route of administration related to the acquired hemophilia A market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACQUIRED HEMOPHILIA A - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive
5 ACQUIRED HEMOPHILIA A - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACQUIRED HEMOPHILIA A - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACQUIRED HEMOPHILIA A - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACQUIRED HEMOPHILIA A - UNMET NEEDS
10 ACQUIRED HEMOPHILIA A - KEY ENDPOINTS OF TREATMENT
11 ACQUIRED HEMOPHILIA A - MARKETED PRODUCTS
11.1 List of Acquired Hemophilia A Marketed Drugs Across the Top 7 Markets
11.1.1 Obizur (Susoctocog alfa) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACQUIRED HEMOPHILIA A - PIPELINE DRUGS
12.1 List of Acquired Hemophilia A Pipeline Drugs Across the Top 7 Markets
12.1.1 Emicizumab - Chugai Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 ACQUIRED HEMOPHILIA A - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ACQUIRED HEMOPHILIA A – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACQUIRED HEMOPHILIA A - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acquired Hemophilia A - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acquired Hemophilia A - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acquired Hemophilia A - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acquired Hemophilia A - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acquired Hemophilia A - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acquired Hemophilia A - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acquired Hemophilia A - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acquired Hemophilia A - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acquired Hemophilia A - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acquired Hemophilia A - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acquired Hemophilia A - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acquired Hemophilia A - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acquired Hemophilia A - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acquired Hemophilia A - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acquired Hemophilia A - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acquired Hemophilia A - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acquired Hemophilia A - Access and Reimbursement Overview
16 ACQUIRED HEMOPHILIA A - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACQUIRED HEMOPHILIA A MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACQUIRED HEMOPHILIA A MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACQUIRED HEMOPHILIA A - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive
5 ACQUIRED HEMOPHILIA A - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACQUIRED HEMOPHILIA A - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACQUIRED HEMOPHILIA A - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACQUIRED HEMOPHILIA A - UNMET NEEDS
10 ACQUIRED HEMOPHILIA A - KEY ENDPOINTS OF TREATMENT
11 ACQUIRED HEMOPHILIA A - MARKETED PRODUCTS
11.1 List of Acquired Hemophilia A Marketed Drugs Across the Top 7 Markets
11.1.1 Obizur (Susoctocog alfa) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACQUIRED HEMOPHILIA A - PIPELINE DRUGS
12.1 List of Acquired Hemophilia A Pipeline Drugs Across the Top 7 Markets
12.1.1 Emicizumab - Chugai Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 ACQUIRED HEMOPHILIA A - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ACQUIRED HEMOPHILIA A – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACQUIRED HEMOPHILIA A - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acquired Hemophilia A - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acquired Hemophilia A - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acquired Hemophilia A - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acquired Hemophilia A - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acquired Hemophilia A - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acquired Hemophilia A - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acquired Hemophilia A - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acquired Hemophilia A - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acquired Hemophilia A - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acquired Hemophilia A - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acquired Hemophilia A - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acquired Hemophilia A - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acquired Hemophilia A - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acquired Hemophilia A - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acquired Hemophilia A - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acquired Hemophilia A - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acquired Hemophilia A - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acquired Hemophilia A - Access and Reimbursement Overview
16 ACQUIRED HEMOPHILIA A - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACQUIRED HEMOPHILIA A MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACQUIRED HEMOPHILIA A MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
